CENTENE CORP 8-K Filing

From the Filing

0001071739-25-000188.txt : 20251110 0001071739-25-000188.hdr.sgml : 20251110 20251110164053 ACCESSION NUMBER: 0001071739-25-000188 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20251110 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20251110 DATE AS OF CHANGE: 20251110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CENTENE CORP CENTRAL INDEX KEY: 0001071739 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance EIN: 041406317 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31826 FILM NUMBER: 251466958 BUSINESS ADDRESS: STREET 1: 7700 FORSYTH BLVD. CITY: ST LOUIS STATE: MO ZIP: 63105 BUSINESS PHONE: 3147254477 MAIL ADDRESS: STREET 1: 7700 FORSYTH BLVD. CITY: ST LOUIS STATE: MO ZIP: 63105 8-K 1 cnc-20251110.htm 8-K cnc-20251110 0001071739 false 0001071739 2025-11-10 2025-11-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2025 CENTENE CORPORATION (Exact Name of Registrant as Specified in Charter) Delaware 001-31826 42-1406317 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 7700 Forsyth Boulevard, St. Louis, Missouri 63105 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: ( 314 ) 725-4477 (Former Name or Former Address, if Changed Since Last Report): N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.001 Par Value CNC New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 7.01 REGULATION FD DISCLOSURE Centene Corporation (the Company) will appear at the UBS 2025 Global Healthcare Conference on Tuesday, November 11, 2025, at 10:15 a.m. EST. At the conference, and in subsequent discussions with investors, members of management will discuss the Company's financial outlook, which is consistent with its previously-issued full year 2025 GAAP forecast of a diluted loss per share not to exceed $(12.85) and full year 2025 adjusted diluted earnings per share (EPS) forecast of at least $2.00. A simultaneous live audio webcast of Centene's participation in the conference on November 11 will be available at https://event.webcasts.com/starthere.jsp?ei=1740257&tp_key=39b5c69ca7&tp_special=8. A webcast replay will be available following the presentation via the Company's website at www.centene.com, under the Investors section. Non-G